Acarodermatitis – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:19:11 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Acarodermatitis – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Comparing effectiveness of topical permethrin, oral ivermectin, and their combination for treating patients with confirmed scabies infection https://clinicaltrials.eu/trial/comparing-effectiveness-of-topical-permethrin-oral-ivermectin-and-their-combination-for-treating-patients-with-confirmed-scabies-infection/ Wed, 29 Apr 2026 15:07:11 +0000 https://clinicaltrials.eu/trial/comparing-effectiveness-of-topical-permethrin-oral-ivermectin-and-their-combination-for-treating-patients-with-confirmed-scabies-infection/ This study focuses on treating scabies, a skin condition caused by tiny mites that burrow under the skin and cause intense itching. The research compares three different treatment approaches: a skin cream containing permethrin, tablets containing ivermectin, and a combination of both treatments. These medications are specifically designed to eliminate the mites that cause scabies.

The study aims to determine which treatment method is most effective at curing scabies in a short time period. Participants will receive either the permethrin cream to apply to their skin, ivermectin tablets to take by mouth, or both treatments together. The treatment period lasts up to one week for the cream and requires up to two doses of the tablets.

During the study, healthcare providers will examine participants’ skin to check how well the treatment is working. They will look for improvements in skin condition and reduction of itching. The total duration of monitoring for each participant is two weeks, during which they will have regular check-ups to assess their response to the treatment and any possible side effects.

]]> Study on Scabies Treatment Comparing 10% Permethrin Cream to 5% Permethrin Cream for Patients with Scabies https://clinicaltrials.eu/trial/study-on-scabies-treatment-comparing-10-permethrin-cream-to-5-permethrin-cream-for-patients-with-scabies/ Wed, 29 Apr 2026 14:27:41 +0000 https://clinicaltrials.eu/trial/study-on-scabies-treatment-comparing-10-permethrin-cream-to-5-permethrin-cream-for-patients-with-scabies/ This clinical trial is focused on studying the treatment of scabies, a skin condition caused by tiny mites that burrow into the skin, leading to itching and rash. The study will compare two creams containing the active ingredient permethrin, which is commonly used to treat scabies. One cream has a concentration of 5%, known as InfectoScab® 5% Cream, and the other is a new formulation with a 10% concentration of permethrin.

The purpose of the study is to determine if the new 10% permethrin cream is more effective than the standard 5% cream in treating scabies. Participants in the study will be randomly assigned to use either the 5% or the 10% permethrin cream. The treatment will be applied to the skin, and the study will last for a period of up to 28 days, depending on the success of the initial treatment. During this time, participants will be monitored to assess the effectiveness and safety of the treatment.

This study is designed to be double-blind, meaning neither the participants nor the researchers will know which concentration of permethrin cream is being used by each participant. This helps ensure that the results are unbiased. The study aims to provide valuable information on whether the higher concentration of permethrin offers better treatment outcomes for people with scabies.

]]> Study on Treating Scabies with Permethrin and Ivermectin for Patients with Scabies https://clinicaltrials.eu/trial/study-on-treating-scabies-with-permethrin-and-ivermectin-for-patients-with-scabies/ Wed, 29 Apr 2026 14:22:43 +0000 https://clinicaltrials.eu/trial/study-on-treating-scabies-with-permethrin-and-ivermectin-for-patients-with-scabies/ This clinical trial is focused on studying the treatment of scabies, a skin condition caused by tiny mites that burrow into the skin, leading to intense itching and a rash. The study will use two main treatments: InfectoScab® 5% cream, which contains the active ingredient permethrin, and a higher concentration permethrin 10% cream. Additionally, DRIPONIN 3 mg tablets, containing ivermectin, may be used if needed. The purpose of the study is to evaluate the effectiveness and safety of these treatments in managing scabies.

The study will be conducted in two stages. In the first stage, participants will receive the standard treatment with InfectoScab® 5% cream, applied once or twice as needed. The success of this treatment will be assessed after 14 or 28 days, depending on the number of applications. If the initial treatment is not successful, the second stage will involve using the higher concentration permethrin 10% cream. Participants in this stage will be divided into different groups to test the effectiveness of one or two applications of the cream, with results evaluated after 14, 21, or 28 days.

Throughout the study, the effectiveness of the treatments will be monitored by checking for the presence of mites and any new skin symptoms. Participants will also be asked about changes in itching levels. The study aims to find the most effective treatment regimen for scabies, ensuring that patients receive the best possible care. The trial will continue until the end of 2026, with the goal of providing valuable insights into the treatment of this common skin condition.

]]>